Protagonist Therapeutics

company

About

Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.

  • 101 - 250

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.34M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2001
Number Of Employee
101 - 250
Operating Status
Active

Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$56.79M
Protagonist Therapeutics has raised a total of $56.79M in funding over 2 rounds. Their latest funding was raised on Sep 6, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 6, 2018 Grant $1.45M 1 National Institutes of Health Detail
May 24, 2017 Grant $1.34M 1 National Institutes of Health Detail
Jul 16, 2015 Series C $40M 2 Detail
Jun 4, 2013 Series B $14M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Protagonist Therapeutics is funded by 3 investors. National Institutes of Health and Pharmstandard International are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Pharmstandard International Series C
Inbio Ventures Series C